A Phase 2 interventional study of Belimumab and Rituximab in Sjogren's Syndrome, sponsored by GlaxoSmithKline. Completed at 36 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Sjogren's Syndrome with a site in France — 18 open to participants now, 25 under way, 7 of them phase 3. Sjogren's Syndrome · France.
Among the 58 studies in Sjogren's Syndrome with a site in France, this one is the 27th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2016, is one of 14 in phase 2, and was the 8th registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →18 of the 58 studies in Sjogren's Syndrome with a site in France are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in France, United States, Australia and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in France, United States, Australia and 17 more countries
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
GlaxoSmithKline · Sites in France, Argentina, Brazil and 6 more countries
Ages 18–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 10 · Phase 4 1
First in 2008; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.
Median enrollment 169 across the 40 interventional studies, 106 across the 18 observational. Of the 26 that completed or were terminated, 9 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 58 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 3 studies filed under Sjogren's Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Sjogren's Syndrome with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05946941Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | 2026-11-18 |
| NCT06741969Phase 3Janssen Research & Development, LLCNipocalimab in Moderate to Severe Sjogren's Disease | 2027-02-04 |
| NCT06875102Centre Hospitalier Universitaire de Saint EtienneFatigue in Sjögren's Syndrome: 3 Therapeutic Strategies | 2027-04 |
| NCT06842316Centre Hospitalier Régional d'OrléansEffects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases | 2027-04-09 |
| NCT03003572Centre Hospitalier Universitaire de Saint EtienneAutoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 58 studies in Sjogren's Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multi-national, multi-center, double-blind (sponsor open), randomized, placebo-controlled trial in subjects with active primary Sjögren's syndrome designed to understand the safety and tolerability profile of belimumab/ rituximab co-administration and of belimumab monotherapy; and to evaluate whether either co-administration therapy or belimumab monotherapy has a substantive effect on disease activity.
This study will consist screening period, double blind treatment period, a general follow-up period and individualized follow-up period. Approximately 70 subjects will be recruited into the study initially. At Day 0, subjects will be randomized 1:2:2:2 to one of the four treatment arms placebo arm, belimumab monotherapy arm, co-administration therapy arm and rituximab monotherapy arm. Once a sufficient number of subjects have completed the Week 24, interim analyses and sample size re-estimation will be conducted. The total number of subjects randomized may increase following sample size re-estimation up to a maximum of 120 recruited into the study.
Subjects in all arms will receive investigational product (IP) until Week 52 (completion of the treatment phase). All subjects will enter a 16-week general follow-up period after the Week 52 visit or after discontinuation if a subject discontinues IP and withdraws from the treatment phase visits prior to Week 52.
After completing the general follow-up period, subjects with cluster of differentiation (CD)19+ B-cell levels below the lower limit of normal (or less than 90 percent [%] of baseline, if baseline value was below lower limit of normal [LLN]) will enter an individualized safety follow-up phase and return to the clinic for visits every 12 weeks with monthly calls between visits to evaluate subjects for any serious adverse events (SAEs) related to IP or study participation, fatal SAEs, and designated adverse event of special interests (AESIs) (i.e., infections, malignancies, or depression, suicide/self-injury), and to check concomitant medications.
The total duration of participation of a subject in this study will be approximately up to a maximum of 2 years (i.e., up to Week 104).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and female subjects; females of child bearing potential are eligible if using effective : Female subject is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotropin [hCG] test), not lactating, and at least one of the following conditions applies:
Non- defined as: Pre-menopausal females with one of the following: Documented tubal ligation, Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Documented Bilateral Oophorectomy.
defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study; otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive belimumab placebo weekly subcutaneous injections to Week 52 and rituximab placebo infusions at Weeks 8 and 10.
Drug: Placebo belimumab · Drug: Placebo rituximab
Subjects will receive 200 mg weekly subcutaneous injections of belimumab to Week 52 and placebo rituximab infusions at Weeks 8 and 10.
Drug: Belimumab · Drug: Placebo rituximab
Subjects will receive belimumab 200 mg SC weekly for 24 weeks followed by weekly placebo belimumab injections to Week 52 with rituximab 1000 mg intravenously at Weeks 8 and 10.
Drug: Belimumab · Drug: Rituximab · Drug: Placebo belimumab
Subjects will receive 1000 mg IV rituximab infusions at Weeks 8 and 10 and weekly subcutaneous injections of placebo belimumab to Week 52.
Drug: Rituximab · Drug: Placebo belimumab
Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.
Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.
The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
Number of Participants With Serious Adverse Events (SAE) and Non-serious AEs (Non-SAE)
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations based on medical or scientific judgment and is associated with liver injury and impaired liver function. Data for number of participants with SAE and non-SAE has been summarized.
Time frame: Up to Week 68
Number of Participants With Adverse Event of Special Interests (AESIs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AESIs were Malignant Neoplasms, Post-Administration Systemic Reactions (PASR), All Infections of Special Interest (opportunistic infections, herpes zoster, tuberculosis and sepsis), Depression/suicide/self-injury, Deaths and study specific AESI which includes: severe skin reaction per GlaxoSmithKline (GSK) Adjudication, cardiac disorders, Posterior Reversible Encephalopathy Syndrome (PRES) and Progressive multifocal leukoencephalopathy (PML). Data for number of participants with AESI has been summarized.
Time frame: Up to Week 68
Change From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) Total Scores Over Time
The ESSDAI is a physician assessed disease activity index developed by EULAR consortium consisting of twelve different clinically relevant organ specific domains; cutaneous, respiratory, renal, articular, muscular, peripheral nervous system, central nervous system, hematological, glandular, constitutional, lymphadenopathy and biological. Each domain has 3 or 4 possible activity levels (i.e., no, low, moderate, high \[if available\]) using a 4-point scale, ranging from 0 (No activity) to 3 (High activity). Higher score indicates high disease activity. Each domain is assigned a weight between 1 and 6. The Total ESSDAI Scores are obtained by multiplying the level of activity (domain score) by the domain weights, ranges between 0 (no activity) and 123 (highest activity). Higher score indicates more disease activity. Baseline value is the screening visit value (within 35 days prior to Day 0). Change from Baseline was defined as the post-dose visit value minus Baseline value.
Time frame: Baseline (Screening [within 35 days prior to Day 0]), Week 12, Week 24, Week 36, Week 52 and Week 68
Stimulated Salivary Flow Rate Over Time
Participants were instructed to chew a piece of paraffin wax for a period of 5 minutes and saliva was collected. The volume of saliva (milliliter) was divided by the duration of the test (minutes) to calculate the stimulated salivary flow rate (milliliter per minute). Baseline value is the screening visit value (within 35 days prior to Day 0).
Time frame: Baseline (Screening [within 35 days prior to Day 0]), Week 12, Week 24, Week 36, Week 52 and Week 68
Oral Dryness Numeric Response Scale (NRS) Over Time
Oral dryness was reported by participants on a numeric response scale, ranging from 0 (no dryness) to 10 (maximal dryness), higher score indicates worst imaginable dryness. Baseline value is the screening visit value (within 35 days prior to Day 0).
Time frame: Baseline (Screening [within 35 days prior to Day 0]), Week 12, Week 24, Week 36, Week 52 and Week 68
Absolute Values for B-cells (Cluster of Differentiation 20 [CD20]) Within Salivary Gland Biopsy at Week 24
Minor salivary gland biopsies were taken for histological analysis to quantify CD20 B Cells.
Time frame: At Week 24
This study was conducted in 10 countries across 31 centers. Participants were randomized to receive one of the four treatments; Placebo, Belimumab + Rituximab Co-administration therapy, Belimumab Monotherapy or Rituximab Monotherapy.
| Milestone | Placebo | Belimumab + Rituximab Co-administration Therapy | Belimumab Monotherapy | Rituximab Monotherapy |
|---|---|---|---|---|
| Started | 13 | 24 | 24 | 25 |
| Completed | 9 | 17 | 19 | 17 |
| Not completed | 4 | 7 | 5 | 8 |
| Withdrew: Adverse event | 1 | 5 | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 | 2 | 5 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 1 |
| Withdrew: Reached stopping criteria | 0 | 0 | 1 | 0 |
| Milestone | Placebo | Belimumab + Rituximab Co-administration Therapy | Belimumab Monotherapy | Rituximab Monotherapy |
|---|---|---|---|---|
| Started | 9 | 17 | 19 | 17 |
| Completed | 8 | 17 | 19 | 16 |
| Not completed | 1 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations based on medical or scientific judgment and is associated with liver injury and impaired liver function. Data for number of participants with SAE and non-SAE has been summarized.
| Participants | Placebo | Belimumab + Rituximab Co-administration Therapy | Belimumab Monotherapy | Rituximab Monotherapy |
|---|---|---|---|---|
| Any SAE | 0 | 3 | 2 | 4 |
| Any non-SAE | 12 | 24 | 23 | 17 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AESIs were Malignant Neoplasms, Post-Administration Systemic Reactions (PASR), All Infections of Special Interest (opportunistic infections, herpes zoster, tuberculosis and sepsis), Depression/suicide/self-injury, Deaths and study specific AESI which includes: severe skin reaction per GlaxoSmithKline (GSK) Adjudication, cardiac disorders, Posterior Reversible Encephalopathy Syndrome (PRES) and Progressive multifocal leukoencephalopathy (PML). Data for number of participants with AESI has been summarized.
| Participants | Placebo | Belimumab + Rituximab Co-administration Therapy | Belimumab Monotherapy | Rituximab Monotherapy |
|---|---|---|---|---|
| Malignant Neoplasms | 0 | 0 | 0 | 1 |
| PASR | 4 | 2 | 3 | 5 |
| All Infections of Special Interest | 2 | 1 | 3 | 2 |
| Depression/Suicide/Self-injury | 0 | 3 | 5 | 1 |
| Deaths | 0 | 1 | 0 | 0 |
| Severe Skin Reactions | 0 | 0 | 0 | 0 |
| Cardiac Disorders | 0 | 1 | 0 | 1 |
| PRES | 0 | 0 | 0 | 0 |
| PML | 0 | 0 | 0 | 0 |
The ESSDAI is a physician assessed disease activity index developed by EULAR consortium consisting of twelve different clinically relevant organ specific domains; cutaneous, respiratory, renal, articular, muscular, peripheral nervous system, central nervous system, hematological, glandular, constitutional, lymphadenopathy and biological. Each domain has 3 or 4 possible activity levels (i.e., no, low, moderate, high \[if available\]) using a 4-point scale, ranging from 0 (No activity) to 3 (High activity). Higher score indicates high disease activity. Each domain is assigned a weight between 1 and 6. The Total ESSDAI Scores are obtained by multiplying the level of activity (domain score) by the domain weights, ranges between 0 (no activity) and 123 (highest activity). Higher score indicates more disease activity. Baseline value is the screening visit value (within 35 days prior to Day 0). Change from Baseline was defined as the post-dose visit value minus Baseline value.
| Scores on a scale | Placebo | Belimumab + Rituximab Co-administration Therapy | Belimumab Monotherapy | Rituximab Monotherapy |
|---|---|---|---|---|
| Week 12; n=8, 17, 19 ,15 | -2.00 ± 1.449 | -4.85 ± 0.996 | -3.87 ± 0.949 | -4.22 ± 1.048 |
| Week 24; n=8, 17, 19 ,16 | -2.87 ± 1.324 | -5.32 ± 0.911 | -3.87 ± 0.869 | -5.25 ± 0.940 |
| Week 36; n=8, 17, 19 ,16 | -3.12 ± 1.520 | -4.09 ± 1.045 | -4.23 ± 0.995 | -4.94 ± 1.079 |
| Week 52;n=8, 17, 19 ,16 | -2.87 ± 1.294 | -5.67 ± 0.890 | -4.76 ± 0.850 | -4.32 ± 0.919 |
| Week 68;n=8, 17, 19 ,16 | -1.75 ± 1.400 | -5.73 ± 0.962 | -3.87 ± 0.918 | -4.38 ± 0.994 |
Participants were instructed to chew a piece of paraffin wax for a period of 5 minutes and saliva was collected. The volume of saliva (milliliter) was divided by the duration of the test (minutes) to calculate the stimulated salivary flow rate (milliliter per minute). Baseline value is the screening visit value (within 35 days prior to Day 0).
| Milliliter per minute | Placebo | Belimumab + Rituximab Co-administration Therapy | Belimumab Monotherapy | Rituximab Monotherapy |
|---|---|---|---|---|
| Baseline (Screening); n=8, 17, 19 ,16 | 0.470 ± 0.2470 | 0.714 ± 0.6294 | 0.425 ± 0.3292 | 0.618 ± 0.6211 |
| Week 12; n=8, 17, 19 ,16 | 0.486 ± 0.2045 | 0.754 ± 0.8342 | 0.493 ± 0.3733 | 0.581 ± 0.5265 |
| Week 24; n=8, 17, 19 ,16 | 0.554 ± 0.3054 | 0.784 ± 0.7900 | 0.454 ± 0.4105 | 0.724 ± 0.8901 |
| Week 36; n=8, 17, 19 ,15 | 0.404 ± 0.2497 | 1.039 ± 1.1027 | 0.506 ± 0.4261 | 0.689 ± 0.5907 |
| Week 52; n=8, 17, 19 ,16 | 0.531 ± 0.3782 | 0.999 ± 1.1457 | 0.582 ± 0.6084 | 0.693 ± 0.7813 |
| Week 68; n=8, 17, 19 ,15 | 0.361 ± 0.1628 | 0.879 ± 0.8167 | 0.517 ± 0.4499 | 0.733 ± 0.7850 |
Oral dryness was reported by participants on a numeric response scale, ranging from 0 (no dryness) to 10 (maximal dryness), higher score indicates worst imaginable dryness. Baseline value is the screening visit value (within 35 days prior to Day 0).
| Scores on a scale | Placebo | Belimumab + Rituximab Co-administration Therapy | Belimumab Monotherapy | Rituximab Monotherapy |
|---|---|---|---|---|
| Baseline (Screening); n= 8, 17, 19, 16 | 7.6 ± 1.51 | 7.4 ± 1.46 | 7.2 ± 2.14 | 7.3 ± 1.91 |
| Week 12; n=8, 17, 19, 16 | 6.1 ± 2.59 | 5.7 ± 1.96 | 6.9 ± 2.32 | 5.1 ± 2.77 |
| Week 24; n=8, 17, 19, 15 | 5.8 ± 2.38 | 5.3 ± 1.83 | 6.8 ± 2.51 | 5.6 ± 2.72 |
| Week 36; n=8, 17, 19, 16 | 5.8 ± 2.76 | 5.9 ± 2.26 | 6.6 ± 2.19 | 6.2 ± 2.51 |
| Week 52; n=8, 17, 19, 16 | 5.6 ± 2.13 | 5.7 ± 1.92 | 7.0 ± 2.40 | 6.3 ± 2.32 |
| Week 68; n=8, 17, 19, 16 | 6.6 ± 2.26 | 6.1 ± 2.63 | 6.9 ± 2.34 | 6.1 ± 2.62 |
Minor salivary gland biopsies were taken for histological analysis to quantify CD20 B Cells.
| Cells per millimeter square | Placebo | Belimumab + Rituximab Co-administration Therapy | Belimumab Monotherapy | Rituximab Monotherapy |
|---|---|---|---|---|
| Absolute Values for B-cells (Cluster of Differentiation 20 [CD20]) Within Salivary Gland Biopsy at Week 24 | 380.21719 ± 569.908102 | 8.65550 ± 20.199794 | 396.86058 ± 781.245844 | 650.76069 ± 1311.360352 |
Collected over Serious adverse events (SAEs) and non-SAEs were collected up to Week 68.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| Belimumab + Rituximab Co-administration Therapy | 1/24 (4.2%) | 3/24 (12.5%) | 24/24 (100%) |
| Belimumab Monotherapy | 0/24 (0%) | 2/24 (8.3%) | 23/24 (95.8%) |
| Rituximab Monotherapy | 0/25 (0%) | 4/25 (16%) | 17/25 (68%) |
| Event | Placebo | Belimumab + Rituximab Co-administration Therapy | Belimumab Monotherapy | Rituximab Monotherapy |
|---|---|---|---|---|
| Enterocolitis infectiousInfections and infestations | 0/13 | 1/24 | 0/24 | 0/25 |
| PneumoniaInfections and infestations | 0/13 | 0/24 | 1/24 | 0/25 |
| PyelonephritisInfections and infestations | 0/13 | 1/24 | 0/24 | 0/25 |
| Atrial flutterCardiac disorders | 0/13 | 1/24 | 0/24 | 0/25 |
| Sjogren's syndromeMusculoskeletal and connective tissue disorders | 0/13 | 0/24 | 1/24 | 0/25 |
| AspirationRespiratory, thoracic and mediastinal disorders | 0/13 | 1/24 | 0/24 | 0/25 |
| BronchitisInfections and infestations | 0/13 | 0/24 | 0/24 | 1/25 |
| Ophthalmic herpes zosterInfections and infestations | 0/13 | 0/24 | 0/24 | 1/25 |
| Cardiac failure acuteCardiac disorders | 0/13 | 0/24 | 0/24 | 1/25 |
| NeutropeniaBlood and lymphatic system disorders | 0/13 | 0/24 | 0/24 | 1/25 |
| Event | Placebo | Belimumab + Rituximab Co-administration Therapy | Belimumab Monotherapy | Rituximab Monotherapy |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/13 | 8/24 | 6/24 | 3/25 |
| PyrexiaGeneral disorders | 4/13 | 3/24 | 2/24 | 2/25 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/13 | 7/24 | 7/24 | 5/25 |
| FatigueGeneral disorders | 3/13 | 6/24 | 2/24 | 2/25 |
| DizzinessNervous system disorders | 0/13 | 2/24 | 6/24 | 2/25 |
| HeadacheNervous system disorders | 2/13 | 5/24 | 4/24 | 6/25 |
| Urinary tract infectionInfections and infestations | 3/13 | 5/24 | 3/24 | 2/25 |
| InfluenzaInfections and infestations | 3/13 | 0/24 | 4/24 | 1/25 |
| DiarrhoeaGastrointestinal disorders | 3/13 | 3/24 | 3/24 | 1/25 |
| RashSkin and subcutaneous tissue disorders | 3/13 | 3/24 | 1/24 | 1/25 |
| Age, Continuous(Years) | Placebo | Belimumab + Rituximab Co-administration Therapy | Belimumab Monotherapy | Rituximab Monotherapy | Total |
|---|---|---|---|---|---|
| Mean | 52.7 ± 12.67 | 45.1 ± 10.93 | 52.0 ± 11.49 | 55.2 ± 15.07 | 51.1 ± 13.06 |
| Sex: Female, Male(Participants) | Placebo | Belimumab + Rituximab Co-administration Therapy | Belimumab Monotherapy | Rituximab Monotherapy | Total |
|---|---|---|---|---|---|
| Female | 13 | 22 | 22 | 23 | 80 |
| Male | 0 | 2 | 2 | 2 | 6 |
| Race/Ethnicity, Customized(Participants) | Placebo | Belimumab + Rituximab Co-administration Therapy | Belimumab Monotherapy | Rituximab Monotherapy | Total |
|---|---|---|---|---|---|
| African American/African Heritage | 1 | 2 | 2 | 1 | 6 |
| American Indian or Alaskan Native | 0 | 0 | 0 | 1 | 1 |
| Asian - East Asian Heritage | 0 | 1 | 1 | 2 | 4 |
| White - Arabic/North African Heritage | 0 | 2 | 3 | 0 | 5 |
| White-White/Caucasian/European Heritage | 12 | 18 | 18 | 21 | 69 |
| African American/African Heritage and Asian Heritage | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Feb 2016 to primary completion in Jun 2020, 52 months.
Results were first posted in Jun 2021, 11 months after primary completion.
Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 52 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Belimumab · Rituximab